Streetbeat News

Analyst Ratings

MAR

Bernstein analyst Richard Clarke has downgraded Marriott Intl (NASDAQ:MAR) from Outperform to Market Perform, while raising the price target from $204 to $218.

Portfolio Pulse from richadhand@benzinga.com

August 14, 2023 | 8:58 am

CF

Barclays analyst Benjamin Theurer has downgraded CF Industries Holdings (NYSE:CF) from Overweight to Equal-Weight, but raised the price target from $80 to $85.

Portfolio Pulse from richadhand@benzinga.com

August 14, 2023 | 8:57 am

MOS

Barclays analyst Benjamin Theurer has downgraded Mosaic (NYSE:MOS) from Equal-Weight to Underweight and set a price target of $40.

Portfolio Pulse from richadhand@benzinga.com

August 14, 2023 | 8:56 am

NTR

Barclays analyst Benjamin Theurer has downgraded Nutrien (NYSE:NTR) from Overweight to Underweight and lowered the price target from $70 to $68.

Portfolio Pulse from richadhand@benzinga.com

August 14, 2023 | 8:54 am

CD

Jefferies analyst Edison Lee has downgraded Chindata Group Holdings (NASDAQ:CD) from Buy to Hold and lowered the price target from $10.73 to $8.6.

Portfolio Pulse from richadhand@benzinga.com

August 14, 2023 | 8:53 am

TDY

Goldman Sachs analyst Noah Poponak has upgraded Teledyne Technologies (NYSE:TDY) from Neutral to Buy and raised the price target from $423 to $495.

Portfolio Pulse from richadhand@benzinga.com

August 14, 2023 | 8:49 am

OKTA

Goldman Sachs analyst Gabriela Borges has upgraded Okta (NASDAQ:OKTA) from Sell to Buy and raised the price target from $77 to $91.

Portfolio Pulse from richadhand@benzinga.com

August 14, 2023 | 8:47 am

GMGI

EF Hutton analyst Michael Albanese has reiterated a 'Buy' rating on Golden Matrix Group (NASDAQ:GMGI) and maintained a $4 price target.

Portfolio Pulse from richadhand@benzinga.com

August 14, 2023 | 8:45 am

LPRO

Canaccord Genuity analyst Joseph Vafi has reiterated a 'Buy' rating on Open Lending (NASDAQ:LPRO) and maintained a price target of $20.

Portfolio Pulse from richadhand@benzinga.com

August 14, 2023 | 8:44 am

TNYA

Chardan Capital analyst Geulah Livshits has reiterated a 'Buy' rating on Tenaya Therapeutics (NASDAQ:TNYA) and maintained a price target of $23.

Portfolio Pulse from richadhand@benzinga.com

August 14, 2023 | 8:37 am